An interventional study of Intervention Hypnosis in Stroke, Traumatic Brain Injury and Multiple Sclerosis, sponsored by Luzerner Kantonsspital. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Luzerner Kantonsspital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.
Among the 216 studies in Stroke with a site in Switzerland, this one is the 87th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2025, is one of 95 with no phase, reaches primary completion later than 49 of the 59 other live ones, and was the 199th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–70
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18–85
School of Health Sciences Geneva · Sites in Switzerland
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 37 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 79 across the 147 interventional studies, 200 across the 69 observational. Of the 134 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 216 have an industry lead sponsor. The 10 most frequent:
Luzerner Kantonsspital is the lead sponsor of 61 studies on the registry; 22 are open to participants now.
Luzerner Kantonsspital has 6 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02756091Insel Gruppe AG, University Hospital BernInternational Intracranial Dissection Study | 2026-11-30 |
| NCT06466772University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT07444151School of Health Sciences GenevaPost-Stroke Fatigue Perception Study (ReFast) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 216 studies in Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This feasibility study investigates the potential of hypnosis as a complementary therapy for improving attentional deficits and reducing fatigue in patients with neurological conditions such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS). These patients often experience reduced spontaneous visual exploration and impaired functional independence despite current rehabilitation approaches. By integrating hypnosis with standard care and using EEG to monitor brain activity during hypnosis and sham-hypnosis sessions, this trial aims to evaluate the feasibility, acceptability, and preliminary efficacy of hypnosis in enhancing attention and reducing fatigue.
Neurological conditions such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS) frequently cause significant impairments in attentional abilities. Commonly accompanying symptoms include visual spatial neglect (VSN) and fatigue syndrome, which exacerbate attentional deficits. These impairments manifest notably as a reduction in spontaneous or free visual exploration (FVE), limiting patients' ability to actively scan and engage with their environment. This diminished visual exploration negatively impacts their capacity to navigate daily surroundings, compromising functional independence and overall quality of life.
Current therapeutic approaches include cognitive rehabilitation, visual exploration training, and non-invasive brain stimulation to promote neuroplasticity and functional recovery. Additionally, management of fatigue focuses on energy regulation strategies in everyday life. Despite these interventions, many patients continue to experience persistent attentional deficits and fatigue after rehabilitation, limiting their ability to perform daily activities and return to previous roles.
Hypnosis is emerging as a promising adjunct therapy in neurological rehabilitation. Widely used in medical fields such as pain management and mental health, hypnosis leverages the brain's ability to enter a state of focused attention and heightened cognitive receptivity, facilitating symptom relief and treatment enhancement without pharmacological side effects. Preliminary evidence suggests hypnosis can improve attentional control and reduce fatigue in neurological populations.
However, research on hypnosis in neurology remains limited, with a need for larger, rigorously controlled studies to confirm its efficacy and understand underlying mechanisms. This feasibility study aims to assess the practicality and acceptability of using hypnosis to treat attentional deficits and fatigue in patients with stroke, TBI, and MS, while also evaluating preliminary efficacy.
A key aspect of this study involves recording electroencephalography (EEG) during both hypnosis and sham-hypnosis sessions. EEG data will provide insight into neural correlates of attentional processing and determine whether hypnosis induces measurable changes in brain activity relative to sham conditions.
Inclusion Criteria:
Exclusion Criteria:
- Psychiatric disease
Exclusion criteria for the EEG:
- Scalp or skin conditions that interfere with EEG electrode placement (e.g. open wounds, infections, severe psoriasis) Implanted medical or neurostimulation devices that interfere with EEG electrode placement (e.g. deep brain stimulators, cochlear implants)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypnosis Intervention Outpatient (Attention-Fatigue) Participants receive hypnosis sessions designed to improve attention and reduce fatigue.
Other: Intervention Hypnosis
Sham Hypnosis Control Participants receive sham hypnosis sessions serving as a control condition.
Other: Intervention Hypnosis
Hypnosis sessions designed to improve attentional control and reduce fatigue in patients with neurological conditions (stroke, TBI, MS). The intervention involves guided hypnotic induction and suggestions tailored to enhance cognitive focus and energy management.
Feasibility of the study design and procedures
The primary objective is to evaluate the feasiblity of conducting the study by assessing the completion rate.
Time frame: From enrollment to the end of treatment at 3 weeks
Video-oculography during free visual exploration
The secondary endpoint is change in eye movement parameters during free visual exploration (FVE) from pre- to post-intervention, measured by video-oculography (mean gaze positions measured in °). Furthermore, between-group differences (hypnosis vs sham-hypnosis) in FVE parameters post-intervention.
Time frame: Change before and after the intervention over the period of 3 weeks.
Plan to share: Undecided
Started Nov 2025 (actual). Primary completion is estimated for Jul 2029, 44 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 44 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luzerner Kantonsspital